Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. The US Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) to convey to the company that its initial review of an application is complete, and it cannot approve the application in its present form. "The CRL did not identify any outstanding scientific issues with the product. The CRL references the requirement for a satisfactory resolution of deficiencies from the pre-approval inspection (PAI) of our Malaysia facility for Insulin Aspart, held in August 2022," Biocon spokesperson said in a regulatory filing. The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the ..
from Latest News https://ift.tt/l7FIngf
via WebMD https://bsmedia.business-standard.com/_media/bs/img/article/2023-04/16/thumb/1681662285-2772.jpg
ABOUT THE AUTHOR
TEAMS FUN AND FAIR - News N Entertainment is your one-stop destination for the latest news, entertainment updates, and product reviews. From breaking headlines and Bollywood buzz to cricket updates and smart shopping recommendations, we bring you curated content that keeps you informed and entertained. Discover trending news from India Today, explore amazing deals on Amazon products including electronics, home decor, furniture, and fashion accessories, and stay updated with sports highlights
